Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing

D J Kereiakes1, T M Broderick, D D Whang

  • 1Carl and Edyth Lindner Center for Clinical Cardiovascular Research, The Health Alliance of Greater Cincinnati, Ohio 45219, USA.

Serious hemorrhage and vascular complications after abciximab therapy are associated with elevated activated clotting time values. Our preliminary experience suggests that low-dose intravenous protamine administration is both safe and effective in reducing elevated in-laboratory activated clotting time values and the potential for serious hemorrhage in abciximab-treated patients.